Reprogramming Urokinase into an Antibody-Recruiting Anticancer Agent
- 18 November 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 7 (2) , 316-321
Abstract
Synthetic compounds for controlling or creating human immunity have the potential to revolutionize disease treatment. Motivated by challenges in this arena, we report herein a strategy to target metastatic cancer cells for immune-mediated destruction by targeting the urokinase-type plasminogen activator receptor (uPAR). Urokinase-type plasminogen activator (uPA) and uPAR are overexpressed on the surfaces of a wide range of invasive cancer cells and are believed to contribute substantially to the migratory propensities of these cells. The key component of our approach is an antibody-recruiting molecule that targets the urokinase receptor (ARM-U). This bifunctional construct is formed by selectively, covalently attaching an antibody-binding small molecule to the active site of the urokinase enzyme. We demonstrate that ARM-U is capable of directing antibodies to the surfaces of target cancer cells and mediating both antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) against multiple human cancer cell lines. We believe that the reported strategy has the potential to inform novel treatment options for a variety of deadly, invasive cancers.Keywords
This publication has 56 references indexed in Scilit:
- A Chemically Induced Vaccine Strategy for Prostate CancerACS Chemical Biology, 2011
- Modulation of tumor immunity by therapeutic monoclonal antibodiesCancer and Metastasis Reviews, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Chemical Control over Immune Recognition: A Class of Antibody-Recruiting Small Molecules That Target Prostate CancerJournal of the American Chemical Society, 2009
- Strategy to Prevent Drug-Related Hypersensitivity in Folate-Targeted Hapten Immunotherapy of CancerThe AAPS Journal, 2009
- Instant immunity through chemically programmable vaccination and covalent self-assemblyProceedings of the National Academy of Sciences, 2009
- Comparing antibody and small-molecule therapies for cancerNature Reviews Cancer, 2006
- Antibody-based therapeutics: Focus on prostate cancerCancer and Metastasis Reviews, 2005
- Inhibition of the invasion capacity of carcinoma cells by WX‐UK1, a novel synthetic inhibitor of the urokinase‐type plasminogen activator systemInternational Journal of Cancer, 2004
- Natural DNP-binding immunoglobulins and antibody multispecificityMolecular Immunology, 1984